JP6951248B2 - がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ - Google Patents

がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ Download PDF

Info

Publication number
JP6951248B2
JP6951248B2 JP2017546075A JP2017546075A JP6951248B2 JP 6951248 B2 JP6951248 B2 JP 6951248B2 JP 2017546075 A JP2017546075 A JP 2017546075A JP 2017546075 A JP2017546075 A JP 2017546075A JP 6951248 B2 JP6951248 B2 JP 6951248B2
Authority
JP
Japan
Prior art keywords
eribulin
pembrolizumab
pharmaceutically acceptable
breast cancer
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017546075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508516A5 (https=
JP2018508516A (ja
Inventor
松井　順二
順二 松井
ガーセル アクタン，
ガーセル アクタン，
ヴァシリキ カランツァ，
ヴァシリキ カランツァ，
ルイロン ユアン，
ルイロン ユアン，
船橋　泰博
泰博 船橋
アーハン ベラック，
アーハン ベラック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55586425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6951248(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2018508516A publication Critical patent/JP2018508516A/ja
Publication of JP2018508516A5 publication Critical patent/JP2018508516A5/ja
Application granted granted Critical
Publication of JP6951248B2 publication Critical patent/JP6951248B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2017546075A 2015-03-04 2016-03-03 がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ Active JP6951248B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128373P 2015-03-04 2015-03-04
US62/128,373 2015-03-04
US201562264068P 2015-12-07 2015-12-07
US62/264,068 2015-12-07
PCT/US2016/020734 WO2016141209A1 (en) 2015-03-04 2016-03-03 Combination of a pd-1 antagonist and eribulin for treating cancer

Publications (3)

Publication Number Publication Date
JP2018508516A JP2018508516A (ja) 2018-03-29
JP2018508516A5 JP2018508516A5 (https=) 2019-04-18
JP6951248B2 true JP6951248B2 (ja) 2021-10-20

Family

ID=55586425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546075A Active JP6951248B2 (ja) 2015-03-04 2016-03-03 がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ

Country Status (13)

Country Link
US (1) US10945990B2 (https=)
EP (1) EP3265122B1 (https=)
JP (1) JP6951248B2 (https=)
KR (1) KR20170122810A (https=)
CN (1) CN107810013B (https=)
AU (1) AU2016226157B2 (https=)
BR (1) BR112017018872A2 (https=)
CA (1) CA2978311A1 (https=)
IL (1) IL254133B (https=)
MX (1) MX386547B (https=)
RU (1) RU2737216C2 (https=)
SG (1) SG11201706872SA (https=)
WO (1) WO2016141209A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CN102369008B (zh) 2009-03-30 2014-10-29 卫材R&D管理有限公司 脂质体组合物
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
NZ738406A (en) * 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
WO2018071792A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
US20190270802A1 (en) * 2016-10-21 2019-09-05 Merck Sharp & Dohme Corp. Treating cancer with a combination of a pd-1 antagonist and an il-27 antagonist
US20200129473A1 (en) * 2017-07-21 2020-04-30 Eisai R&D Management Co., Ltd. Use of eribulin and cyclin dependent kinase inhibitors in the treatment of cancer
WO2019097073A1 (en) 2017-11-20 2019-05-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
AU2019285640A1 (en) * 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
JP2021535187A (ja) 2018-06-15 2021-12-16 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ｓ−エクオールを用いた黒色腫の処置及び予防方法
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) * 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
JP2022553421A (ja) * 2019-10-28 2022-12-22 エンジーケム ライフサイエンシーズ コーポレーション がんの処置のための方法および組成物
WO2025049528A1 (en) * 2023-08-29 2025-03-06 Cullinan Amber Corp. Combination therapies for cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4454151B2 (ja) 1998-06-17 2010-04-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 大環状類似体及びそれらの使用並びに調製方法
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
SI2522663T1 (sl) 2004-06-03 2015-08-31 Eisai R&D Management Co., Ltd. Vmesne spojine za pripravo halihondrina B
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
BRPI0817909B1 (pt) 2007-10-03 2022-06-21 Eisai R&D Management Co., Ltd Métodos de obtenção e de preparação de uma composição diastereomericamente pura, compostos, e método para produzir os referidos compostos
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
RU2579511C2 (ru) 2010-01-26 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные фуро[3,2-в]пирана, применимые в синтезе аналогов
JP2014508165A (ja) 2011-03-02 2014-04-03 モルフォテック、インク． 乳癌の治療のためのエリブリンおよびファーレツズマブの共投与
EP2686441B1 (en) * 2011-03-18 2019-05-08 Eisai R&D Management Co., Ltd. Methods and uses for predicting response to eribulin
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
RU2689977C2 (ru) * 2012-12-04 2019-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина для лечения рака молочной железы
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
WO2014159562A1 (en) * 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
ES2822665T3 (es) * 2013-05-31 2021-05-04 Merck Sharp & Dohme Terapias de combinación para el cáncer
CA2912346A1 (en) 2013-06-11 2014-12-18 Novartis Ag Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
BR112015029386B1 (pt) * 2013-06-26 2023-11-14 Eisai R&D Management Co., Ltd. Uso de eribulina e lenvatinibe como terapia de combinação e kit
US9457019B2 (en) * 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
KR20240144452A (ko) * 2014-03-05 2024-10-02 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 이용한 신장암의 치료
US20170100367A1 (en) 2014-05-28 2017-04-13 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of cancer
AU2016226157B2 (en) 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer

Also Published As

Publication number Publication date
MX2017011206A (es) 2018-05-17
AU2016226157A1 (en) 2017-09-14
IL254133B (en) 2021-09-30
US10945990B2 (en) 2021-03-16
AU2016226157B2 (en) 2022-01-27
CN107810013A (zh) 2018-03-16
EP3265122A1 (en) 2018-01-10
BR112017018872A2 (pt) 2018-05-29
RU2737216C2 (ru) 2020-11-26
RU2017132877A3 (https=) 2019-08-29
JP2018508516A (ja) 2018-03-29
CN107810013B (zh) 2021-04-02
MX386547B (es) 2025-03-19
WO2016141209A1 (en) 2016-09-09
SG11201706872SA (en) 2017-09-28
KR20170122810A (ko) 2017-11-06
RU2017132877A (ru) 2019-04-05
IL254133A0 (en) 2017-10-31
US20180071247A1 (en) 2018-03-15
CA2978311A1 (en) 2016-09-09
EP3265122B1 (en) 2022-05-04

Similar Documents

Publication Publication Date Title
JP6951248B2 (ja) がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
JP7507209B2 (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
JP6812512B2 (ja) 癌を治療するためのｐｄ−１アンタゴニストおよびｉｄｏ１阻害剤の組み合わせ
KR102232153B1 (ko) Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료
JP2020117524A (ja) 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
JP2020007359A (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
KR20200119845A (ko) 항 pd-1 항체 및 항 ctla4 항체를 사용한 암의 치료 방법
US20180044418A1 (en) Combination of a pd-1 antagonist and vorinostat for treating cancer
US20190263927A1 (en) Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
HK1232153B (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210831

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210924

R150 Certificate of patent or registration of utility model

Ref document number: 6951248

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250